Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 7,256 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Alcohol Drinking, Drinking Behavior, At-risk Drinking, Cardiovascular Risk Factor, High Blood Pressure
Interventions: Alcohol Abstinence, Control arm; Behavioral · Other
Lead sponsor: The University of Texas at Arlington; Other
Eligibility: 26 Years to 49 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Arlington, Texas

Conditions: Contraceptive Usage, Alcohol Use Complicating Childbirth, Alcohol Drinking
Interventions: Native-CHOICES; Behavioral
Lead sponsor: Washington State University; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Eagle Butte, South Dakota • Rapid City, South Dakota

Conditions: Pancreatic Cyst, Pancreas Disease
Interventions: Bio-Specimen Collection; Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Stanford, California

Conditions: Breast Augmentation, Breast Revision-Augmentation
Interventions: Sientra 207 Silicone Gel Breast Implant; Device
Lead sponsor: Tiger Biosciences, LLC.; Industry
Eligibility: 22 Years and older · Female only
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Prostate Cancer
Interventions: Docetaxel, Dexamethasone, Estramustine, Zoladex, Casodex, Radical Prostatectomy; Drug · Procedure
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsed/Refractory Ovarian Carcinoma
Interventions: NTB-928; Drug
Lead sponsor: TeneoSeven, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more

Conditions: Physical Activity
Interventions: HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension
Interventions: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 11,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Cancer
Interventions: HER-2 pulsed Dendritic Cell Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Cancer
Interventions: radiation therapy; Radiation
Lead sponsor: Gustave Roussy, Cancer Campus, Grand Paris; Other
Eligibility: Up to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Anifrolumab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 6
States / cities: Thousand Oaks, California • Orlando, Florida • New York, New York + 3 more

Conditions: Brain Cancer
Interventions: Fluorescein, Fluorescein + ALA; Drug
Lead sponsor: David W. Roberts; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
Interventions: Carfilzomib, Tacrolimus; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Blasts 10-19 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, High Risk Chronic Myelomonocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
Interventions: Liposome-encapsulated Daunorubicin-Cytarabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fasting
Interventions: Fasting; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 20 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Davis, California

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Bortezomib, Dexamethasone, Autologous Stem Cell Transplant; Drug · Procedure
Lead sponsor: Paul Richardson, MD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2026
U.S. locations: 46
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 37 more

Conditions: Asthma
Interventions: fluticasone furoate, albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Long Beach, California • Newport Beach, California • Colorado Springs, Colorado + 16 more

Conditions: Multiple Myeloma
Interventions: Allopurinol, Carmustine, Etoposide, Cytarabine, Melphalan; Drug
Lead sponsor: Swedish Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: Human Regular U-500 Insulin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 35
States / cities: Mobile, Alabama • Little Rock, Arkansas • Concord, California + 32 more

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Interventions: Cladribine, Cytarabine, Filgrastim, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Mitoxantrone, Sorafenib; Drug · Biological · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: High Health Care-utilizing Medicaid Beneficiaries
Interventions: Supportive services; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Anal High Grade Squamous Intraepithelial Lesion, Anal Precancerous Condition, AIN 2/3, HPV Infection, Anal Dysplasia, HPV Disease
Interventions: Artesunate, Placebo; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 25 Years and older · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Small-Cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd); Biological
Lead sponsor: Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more

Search by objective public record fields.

Reducing Cardiovascular Risks: The Role of Alcohol Use

Native-Changing High-risk Alcohol Use and Increasing Contraception Effectiveness Study

Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer

Post Market Clinical Experience Study of Sientra 207 Breast Implants

Docetaxel Followed by Radical Prostatectomy in Patients With High Risk Localized Prostate Cancer

Study of NTB-928 in R/R OC

An mHealth Mobile Application Supporting Maintenance of Physical Activity Among Men and Women With High Blood Pressure

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension

HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations

Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Effects of Prolonged Fasting on Microbiome and HDL

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Evaluating the Efficacy and Safety of Fluticasone Furoate in the Treatment of Asthma in Adults and Adolescents

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Evaluation of a Community Health Worker (CHW)-Led Program

Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL

Adherence to Intensive Surveillance for Hereditary Breast Cancer

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)